Comparison between in-person, telehealth, and combination visits among veterans treated in a pharmacist-led diabetes management clinic

J Am Pharm Assoc (2003). 2024 Jul-Aug;64(4):102121. doi: 10.1016/j.japh.2024.102121. Epub 2024 May 10.

Abstract

Background: The Veterans Affairs San Diego Healthcare System converted its pharmacist-run Diabetes Intense Medical Management Clinic to telehealth during the COVID-19 pandemic. Previous studies suggested that in-person DIMM visits improved glycemic control, medication adherence, and patient satisfaction. To explore if these benefits apply to telehealth, we compared glycemic control in veterans with post-COVID-19 telehealth DIMM visits and prepandemic in-person DIMM visits.

Objective: The primary study objective was to evaluate the mean hemoglobin (A1c) change from baseline in cohorts who received telehealth visits, traditional visits, or a combination of both after 12 months of intervention. Secondary objectives included evaluation of all-cause mortality and the average time to mortality (days).

Methods: A retrospective multiarm historical cohort control study was conducted to compare 12-month glycemic control among veterans with type 2 diabetes who initiated DIMM care via audio-only telehealth, in-person, or combination between August 2018 and November 2021. Primary endpoint was the 12-month change in A1c from baseline; secondary measures included all-cause mortality and the average time to mortality (days).

Results: A total of 44 veterans were included for analysis. At 12 months, the average decreases in A1c from baseline were -0.90% (95% CI: -2.82, 1.01), -1.73% (95% CI: -3.33, -0.14), and -1.42% (95% CI: -2.67, -0.18) for the In-Person, Telehealth, and Combination groups, respectively. No differences in quarterly HbA1c rate of change were reported across the groups. All-cause mortality was highest in the In-person group (15.4%) compared to the Telehealth (4.6%) and the Combination (0.0%) groups; however, these differences were not statistically significant. Lastly, there were no significant differences in average time to death between the groups.

Conclusion: Telehealth may be an alternative method of access to pharmacist-led diabetes care that is slowly making its way into our healthcare systems as a permanent fixture.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • COVID-19* / mortality
  • California
  • Diabetes Mellitus, Type 2* / drug therapy
  • Female
  • Glycated Hemoglobin* / analysis
  • Glycated Hemoglobin* / metabolism
  • Glycemic Control / methods
  • Historically Controlled Study
  • Humans
  • Hypoglycemic Agents / administration & dosage
  • Hypoglycemic Agents / therapeutic use
  • Male
  • Medication Adherence / statistics & numerical data
  • Middle Aged
  • Pharmaceutical Services / organization & administration
  • Pharmacists* / organization & administration
  • Retrospective Studies
  • Telemedicine* / statistics & numerical data
  • United States
  • United States Department of Veterans Affairs
  • Veterans* / statistics & numerical data

Substances

  • Glycated Hemoglobin
  • Hypoglycemic Agents
  • hemoglobin A1c protein, human